Amir Parsa Abhari

Dr. Amir Parsa Abhari


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2024 in Biological Trace Element Research
Verified
Journal Article
Open access
PDF file
SMSadegh Mazaheri-Tehrani
Sadegh Mazaheri-Tehrani
AAAmir Parsa Abhari
Amir Parsa Abhari
NONegar Ostadsharif
Negar Ostadsharif
ASArman Shekarian
Arman Shekarian
MVMahshad Vali
Mahshad Vali
Marek KieliszekMarek Kieliszek
Marek Kieliszek
Selenium is a trace element with pivotal roles in metabolic processes. Studies suggested that selenium deficiency could lead to impaired lipid profiles. However, inconsistent results have been reported regarding the association between serum selenium concentrations and lipid profile (triglycerides, LDL, HDL, VLDL, and total cholesterol). Thus, we aimed to review the correlation between them. A systematic literature search was conducted in PubMed, Embase, Web of Science, Scopus, and Google Scholar until 31 December 2023. The relevant correlation coefficients were used as desired effect sizes to assess the correlation between selenium level and lipid profile. Among 8291 records found in the primary search, 47 and 34 articles were included in the systematic review and meta-analysis, respectively. All included studies were observational investigations and had acceptable quality. Our results failed to reach strong evidence supporting the correlation between serum selenium level and lipid profiles, except for HDL, which showed a weak correlation among both adults (r = 0.1 [0.03:0.17]; I 2 = 71%) and pediatrics (r = 0.08 [0.03:0.14]; I 2 = 38%). Subgroup analyses based on gender did not reveal a significant or strong correlation with selenium levels (except for total cholesterol in males (r = 0.12 [0.01:0.22]; I 2 = 52%)). The results did not change after the sensitivity analysis. Although some previous studies have suggested that selenium deficiency could lead to impaired lipid profile, the findings of this study indicate no strong correlation between serum selenium levels and lipid profile.

2 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MMMohammad R. Movahed
Mohammad R. Movahed
AAAmir Parsa Abhari
Amir Parsa Abhari
MHMehrtash Hashemzadeh
Mehrtash Hashemzadeh
Introduction: The obesity paradox has been observed in patients with cardiovascular disease. The goal of this study was to evaluate whether obesity has a protective effect in patients presenting with an ST elevation myocardial infarction (STEMI). Method: Using the large Nationwide Inpatient (NIS) sample database, we evaluated the mortality in patients with a STEMI based on weight categories. Results: A total of 2,161,640 STEMI patients were found in the database over age 18. We found that overweight and obesity had the lowest mortality using univariate (overweight mortality of 5% vs. obesity mortality of 6.5% vs. 10.9% for normal weights) and multivariate analyses (overweight OR: 0.52, CI: 0.43–063; p < 0.001 and obesity OR: 0.7, CI: 0.67–0.74; p < 0.001), whereas cachexia was associated with the highest mortality in the univariate (cachexia 24.5%) and multivariate (OR: 2.28, CI: 2.13–2.44; p < 0.001) analyses, followed by morbid obesity in the multivariate analysis (OR: 1.07, CI: 1.02–1.12; p = 0.004). Conclusions: We observed a partial obesity paradox in patients with a STEMI showing that overweight have the best survival rates followed by obesity. Cachexia followed by morbid obesity had the lowest survival rates.

3 April 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
RAReza Amani-Beni
Reza Amani-Beni
BDBahar Darouei
Bahar Darouei
DSdavood shafie
davood shafie
MMMohammadreza Mortaheb
Mohammadreza Mortaheb
MMMohammadreza Malakoutikhah
Mohammadreza Malakoutikhah
MHMaryam Heidarpour
Maryam Heidarpour
Managing electrolyte abnormalities, particularly sodium and potassium, in patients with heart failure (HF) remains a concern. A novel anti-diabetic drug, sodium-glucose co-transporter-2 (SGLT2) inhibitors, has become suitable for HF patients, improving cardiovascular outcomes. Therefore, we aimed to conduct a meta-analysis to evaluate the effect of SGLT2 inhibitors on serum sodium and potassium. We systematically searched five databases, identifying randomized clinical trials (RCTs) reporting changes in serum sodium and potassium levels with SGLT2 inhibitors compared to comparator groups. Outcomes were presented as weighted mean differences (WMD) and standardized MD (SMD) with 95% confidence intervals (CI). Subgroup and sensitivity analyses were also conducted. 13 studies were included, with 13 studies with 10,617 participants reporting on serum sodium and nine studies with 9877 participants on serum potassium. In acute HF, SGLT2 inhibitors did not significantly affect serum sodium (WMD: 1.21 mmol/L; 95% CI: − 0.79, 3.21) or potassium levels (WMD: 0.11 mEq/L; 95% CI: − 0.20, 0.42). Subgroup analyses suggested possible variations by follow-up duration (< 7 days vs. ≥ 30 days) and drug type, but findings remained non-significant. Sensitivity analysis using the leave-one-out method and risk of bias assessment results showed no considerable changes in the statistical significance of the pooled results. Similarly, in chronic HF, no significant differences were observed for serum sodium (WMD: 0.23 mmol/L; 95% CI: − 0.45, 0.91) or potassium (WMD: 0.07 mEq/L; 95% CI: − 0.29, 0.44). Sensitivity and subgroup analyses based on duration, drug type, diabetes status, renal function, or systolic blood pressure did not reveal clinically meaningful differences across all analyses. For all analyses, Egger’s test was non-significant, indicating no strong evidence of small‐study effects. Moreover, the trim-and-fill method combined with the funnel plot did not identify any missing studies, and the recalculated effect size remained unchanged. SGLT2 inhibitors did not significantly alter serum sodium or potassium levels in acute or chronic HF, suggesting that these drugs can be safe regarding electrolyte disturbances. Additional RCTs are warranted to enhance the robustness of evidence regarding the mechanisms and effects of SGLT2 inhibitors on serum electrolyte levels, considering variations across different types of SGLT2 inhibitors.

4 April 2025 in Cardiology in Review
Verified
Journal Article
Closed access
FAFarzad Adelparvar
Farzad Adelparvar
MFMohammad Fakhrolmobasheri
Mohammad Fakhrolmobasheri
FQFatemeh Qorbani
Fatemeh Qorbani
DSDavood Shafie
Davood Shafie
MHMaryam Heidarpour
Maryam Heidarpour
AAAmir Parsa Abhari
Amir Parsa Abhari
Pulmonary hypertension (PH) is a chronic disease characterized by elevated pulmonary arterial pressure, often leading to right ventricular failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are potential therapies for PH due to their cardiovascular effects. In this systematic review, we aim to assess the safety and efficacy of SGLT2 inhibitors in improving pulmonary hemodynamics and cardiac parameters in patients with PH. A systematic review search until November 2024 was conducted across 8 databases. Six studies involving 462 participants were included, comprising 3 randomized controlled trials, 2 observational studies, and 1 cohort study. SGLT2 inhibitors, particularly dapagliflozin and empagliflozin, significantly reduced pulmonary arterial pressure in most studies. Cardiac indices, such as left ventricular diastolic and systolic diameters, E/e’, and left ventricular ejection fraction, also improved. However, one randomized controlled trial reported no significant improvement in the hemodynamic outcomes. SGLT2 inhibitors are assumed to be promising in the management of PH through cardiac and hemodynamic improvements. Further research is needed to elucidate their efficacy and the underlying mechanisms.

22 March 2023 in Cardiology in Review
Verified
Journal Article
Closed access
DSDavood Shafie
Davood Shafie
AAAmir Parsa Abhari
Amir Parsa Abhari
MFMohammad Fakhrolmobasheri
Mohammad Fakhrolmobasheri
Owing to the augmented perception of heart failure (HF) pathophysiology, management of the affected patients has been improved dramatically; as with the identification of the inflammatory background of HF, new avenues of HF prognosis research have been opened up. In this regard, relative values of hematologic indices were demonstrated by a growing body of evidence to successfully predict HF outcomes. Cost-effectiveness, accessibility, and easy obtainability of these relative values make them a precious option for the determination of HF prognosis; particularly in low-income developing countries. In this short review, we aimed to present the current literature on the predictability of these hematologic parameters for HF outcomes.

1 May 2024
Verified
Journal Article
Closed access
SHSeyed Reza Hosseini
Seyed Reza Hosseini
MGMaryam Gholamnejad
Maryam Gholamnejad
MMMohammad Ghassem Mohseni
Mohammad Ghassem Mohseni
AAAmir Parsa Abhari
Amir Parsa Abhari
SASeyed Mohammad Kazem Aghamir
Seyed Mohammad Kazem Aghamir
Objective: Utilizing the combination of fluoroscopy and ultrasonography during Percutaneous Nephrolithotomy (PCNL) to minimize radiation exposure. Methods: In this randomized clinical trial, 118 patients with urinary stones who were candidates for PCNL surgery in the prone position were selected and divided into two groups (with an allocation ratio of 1:1). Cases were grouped according to whether ultrasonography was used for renal tract dilation and Amplatz sheath placement. The number of attempts to establish proper renal access, the time interval between access to the targeted calyx and nephroscope entrance, and the Clavien-Dindo score were collected. Results: The mean age of all patients was 46.12 +/- 11.28 (45.6 +/- 11.2 in the total fluoroscopy group and 46.5 +/- 11.4 in the combined group) years (20-66). The intergroup differences in the baseline features were not significant. The mean duration of fluoroscopy time was significantly reduced in the combined guidance group (36.22 +/- 10.73 vs. 23.05 +/- 8.94 seconds, ( P -value = 0.001). Moreover, the difference in the distribution of Amplatz location on the nephroscopy time was meaningful ( P -value = 0.016). However, intergroup differences in the number of attempts to successful puncture, length of hospitalization, recovery time, and postoperative complications, including gross hematuria duration, blood loss volume, pack cells requirement, pain score immediately and 6 hours after the surgery, and Clavien-Dindo score were not meaningful. Conclusion: It can be concluded that the use of ultrasound with X-ray in prone PCNL compared to the use of X-rays alone can significantly reduce the duration of radiation without increasing the risk of intra-operative and postoperative detrimental events.